Bryan G. Johnson

5.8k citations
59 papers · 4.6k · 1 hit paper · h-index 33

Impact in

Papers in

  • Cellular and Molecular Neuroscience 53
    • Neuroscience and Neuropharmacology Research 49
    • Photoreceptor and optogenetics research 7
  • Molecular Biology 42
    • Receptor Mechanisms and Signaling 30
    • Ion channel regulation and function 17
    • Pharmacological Receptor Mechanisms and Effects 7
    • Chemical Synthesis and Analysis 5
Co-authors
Darryle D. Schoepp (42 shared papers)James A. Monn (22 shared papers)Rebecca A. Wright (30 shared papers)Craig R. Salhoff (15 shared papers)J. Paul Burnett (6 shared papers)Nancy G. Mayne (6 shared papers)Paul L. Ornstein (6 shared papers)Joseph P. Tizzano (11 shared papers)
Journals
Journal of Medicinal Chemistry (13 papers)Neuropharmacology (12 papers)Journal of Pharmacology and Experimental Therapeutics (6 papers)Journal of Neurochemistry (6 papers)Bioorganic & Medicinal Chemistry Letters (3 papers)
Partner nations
United StatesUnited KingdomSpain

In The Last Decade

Bryan G. Johnson

58 papers receiving 4.5k citations

Bryan G. Johnson's Hit Papers

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial 2007 · 790 citations
7900+6+12Years since publication250500750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

  • it has ≥500 total citations;
  • it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
  • it reaches the top citation threshold in at least one of its specific research topics.
  1. 2007 Nature Medicine

Peers

Bryan G. Johnson
Comparison fields: 5 of 99
  • Cellular and Molecular Neuroscience 3.8k
  • Biological Psychiatry 281
  • Molecular Biology 2.8k
  • Cognitive Neuroscience 728
  • Neurology 222
Replace Vincent Mutel with:
Vincent Mutel Switzerland
Mark A. Varney United States
Frédéric Knoflach Switzerland
Henry Sershen United States
Carrie K. Jones United States
Paul L. Ornstein United States
Alan H. Ganong United States
Kevin K. Ogden United States
James A. Monn United States
James N.C. Kew United Kingdom
Bryan G. Johnson relative to Vincent Mutel Switzerland Vincent Mutel's profile →
Citations per field
00.5×1.5×
Vincent Mutel · 1×
Citations per year

Countries citing papers authored by Bryan G. Johnson

Since Specialization
Citations

This map shows the geographic impact of Bryan G. Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bryan G. Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bryan G. Johnson more than expected).

Fields of papers citing papers by Bryan G. Johnson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bryan G. Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bryan G. Johnson. The network helps show where Bryan G. Johnson may publish in the future.

Co-authors

The 25 scholars most cited alongside Bryan G. Johnson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Bryan G. Johnson Line = papers co-authored together Bryan G. Johnson links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 59 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial
Nature Medicine ·Sandeep T. Patil, Lu Zhang, Ferenc Martényi, Stephen L. Lowe, Kimberley Jackson, Andreev Bv, А С Аведисова, L. M. Bardenstein, Issak Y Gurovich, Morozova Ma, Sergey Mosolov, Н. Г. Незнанов, A M Reznik, Smulevich Ab, В А Точилов, Bryan G. Johnson, James A. Monn, Darryle D. Schoepp
Hit paper breakdown →		2007790
2
Design, Synthesis, and Pharmacological Characterization of (+)-2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY354740):  A Potent, Selective, and Orally Active Group 2 Metabotropic Glutamate Receptor Agonist Possessing Anticonvulsant and Anxiolytic Properties
Journal of Medicinal Chemistry ·James A. Monn, Matthew J. Valli, Steven M. Massey, Rebecca A. Wright, Craig R. Salhoff, Bryan G. Johnson, Trevor Howe, Charles A. Alt, Gary A. Rhodes, Roger L. Robey, Kelly R. Griffey, Joseph P. Tizzano, Mary Jeanne Kallman, David R. Helton, Darryle D. Schoepp
1997337
3
LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors
Neuropharmacology ·Anne Kingston, Paul L. Ornstein, Rebecca A. Wright, Bryan G. Johnson, Nancy G. Mayne, J. Paul Burnett, Rama M. Belagaje, Song Wu, Darryle D. Schoepp
1998316
4
Synthesis, Pharmacological Characterization, and Molecular Modeling of Heterobicyclic Amino Acids Related to (+)-2-Aminobicyclo[3.1.0]hexane- 2,6-dicarboxylic Acid (LY354740):  Identification of Two New Potent, Selective, and Systemically Active Agonists for Group II Metabotropic Glutamate Receptors
Journal of Medicinal Chemistry ·James A. Monn, Matthew J. Valli, Steven M. Massey, Marvin M. Hansen, Thomas Kress, James P. Wepsiec, Allen R. Harkness, John L. Grutsch, Rebecca A. Wright, Bryan G. Johnson, Sherri L. Andis, Ann E. Kingston, Rosemarie Tomlinson, Richard A. Lewis, Kelly R. Griffey, Joseph P. Tizzano, Darryle D. Schoepp
1999242
5
3,5‐Dihydroxyphenylglycine Is a Highly Selective Agonist for Phosphoinositide‐Linked Metabotropic Glutamate Receptors in the Rat Hippocampus
Journal of Neurochemistry ·Darryle D. Schoepp, John Goldsworthy, Bryan G. Johnson, Craig R. Salhoff, Stephen Baker
1994241
6
LY354740 is a Potent and Highly Selective Group II Metabotropic Glutamate Receptor Agonist in Cells Expressing Human Glutamate Receptors
Neuropharmacology ·Darryle D. Schoepp, Bryan G. Johnson, Rebecca A. Wright, Craig R. Salhoff, Nancy G. Mayne, Sheng‐Nan Wu, Sandra L. Cockerham, J. Paul Burnett, R BELEGAJE, David Bleakman, James A. Monn
1997193
7
Excitatory Amino Acid Agonist‐Antagonist Interactions at 2‐Amino‐4‐Phosphonobutyric Acid‐Sensitive Quisqualate Receptors Coupled to Phosphoinositide Hydrolysis in Slices of Rat Hippocampus
Journal of Neurochemistry ·Darryle D. Schoepp, Bryan G. Johnson
1988167
8
Evidence for the Role of Metabotropic Glutamate (mGlu)2 Not mGlu3 Receptors in the Preclinical Antipsychotic Pharmacology of the mGlu2/3 Receptor Agonist (–)-(1 R, 4 S,5 S,6 S)-4-Amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic Acid (LY404039)
Journal of Pharmacology and Experimental Therapeutics ·Matthew Fell, Kjell Svensson, Bryan G. Johnson, Darryle D. Schoepp
2008159
9
Inhibition of Cyclic AMP Formation by a Selective Metabotropic Glutamate Receptor Agonist
Journal of Neurochemistry ·Darryle D. Schoepp, Bryan G. Johnson, James A. Monn
1992140
10
In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders
Psychopharmacology ·Linda M. Rorick‐Kehn, Bryan G. Johnson, Karen M. Knitowski, Craig R. Salhoff, Jeffrey M. Witkin, Kenneth W. Perry, Kelly I. Griffey, Joseph P. Tizzano, James A. Monn, David L. McKinzie, Darryle D. Schoepp
2007131
11
Stereoselectivity and mode of inhibition of phosphoinositide-coupled excitatory amino acid receptors by 2-amino-3-phosphonopropionic acid.
Molecular Pharmacology ·Darryle D. Schoepp, Bryan G. Johnson, Edward C. Smith, Loretta A. McQuaid
199096
12
Group III human metabotropic glutamate receptors 4, 7 and 8: Molecular cloning, functional expression, and comparison of pharmacological properties in RGT cells
Molecular Brain Research ·Su Wu, Rebecca A. Wright, Pamela K. Rockey, Stanley G. Burgett, Jeffrey S. Arnold, Paul R. Rosteck, Bryan G. Johnson, Darryle D. Schoepp, Rama M. Belagaje
199888
13
The Novel Metabotropic Glutamate Receptor Agonist 2 R ,4 R -APDC Potentiates Stimulation of Phosphoinositide Hydrolysis in the Rat Hippocampus by 3,5-dihydroxyphenylglycine: Evidence for a Synergistic Interaction Between Group 1 and Group 2 Receptors
Neuropharmacology ·Darryle D. Schoepp, Craig R. Salhoff, Rebecca A. Wright, Bryan G. Johnson, J. Paul Burnett, Nancy G. Mayne, Rama M. Belagaje, Song Wu, James A. Monn
199688
14
2-Substituted (2SR)-2-Amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as Potent and Selective Antagonists of Group II Metabotropic Glutamate Receptors. 2. Effects of Aromatic Substitution, Pharmacological Characterization, and Bioavailability
Journal of Medicinal Chemistry ·Paul L. Ornstein, Thomas J. Bleisch, M. Brian Arnold, Joseph H. Kennedy, Rebecca A. Wright, Bryan G. Johnson, Joseph P. Tizzano, David R. Helton, Mary Jeanne Kallman, Darryle D. Schoepp, Marc Hérin
199886
15
Increased anxiety-related behavior in mice deficient for metabotropic glutamate 8 (mGlu8) receptor
Neuropharmacology ·A. Linden, Bryan G. Johnson, Steven Peters, H E Shannon, Ming Ting Tian, Y Wang, Jianliang Yu, Anja Köster, M Baez, Darryle D. Schoepp
200283
16
Sigma opioid receptor: characterization and co-identity with the phencyclidine receptor.
Journal of Pharmacology and Experimental Therapeutics ·Laura G. Mendelsohn, D. Kalra, Bryan G. Johnson, Gail A. Kerchner
198578
17
Pharmacological and Pharmacokinetic Properties of a Structurally Novel, Potent, and Selective Metabotropic Glutamate 2/3 Receptor Agonist: In Vitro Characterization of Agonist (–)-(1 R,4 S,5 S,6 S)-4-Amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic Acid (LY404039)
Journal of Pharmacology and Experimental Therapeutics ·Linda M. Rorick‐Kehn, Bryan G. Johnson, Jennifer Burkey, Rebecca A. Wright, David O. Calligaro, Gerard J. Marek, Eric S. Nisenbaum, John T. Catlow, Ann E. Kingston, Deborah D. Giera, Marc Hérin, James A. Monn, David L. McKinzie, Darryle D. Schoepp
200777
18
Comparison of (1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid (1S,3R-ACPD)- and 1R,3S-ACPD-stimulated brain phosphoinositide hydrolysis
European Journal of Pharmacology Molecular Pharmacology ·Darryle D. Schoepp, Bryan G. Johnson, Rebecca A. True, James A. Monn
199176
19
CNS distribution of metabotropic glutamate 2 and 3 receptors: Transgenic mice and [3H]LY459477 autoradiography
Neuropharmacology ·Rebecca A. Wright, Bryan G. Johnson, Ce Zhang, Craig R. Salhoff, Ann E. Kingston, David O. Calligaro, James A. Monn, Darryle D. Schoepp, Gerard J. Marek
201272
20
Comparison of Excitatory Amino Acid‐Stimulated Phosphoinositide Hydrolysis and N‐[3H]Acetylaspartylglutamate Binding in Rat Brain: Selective Inhibition of Phosphoinositide Hydrolysis by 2‐Amino‐3‐Phosphonopropionate
Journal of Neurochemistry ·Darryle D. Schoepp, Bryan G. Johnson
198971

About Bryan G. Johnson

Bryan G. Johnson is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology, Materials Chemistry, Spectroscopy and Cognitive Neuroscience, having authored 59 papers that have together received 4.6k indexed citations. Recurring topics across this work include Neuroscience and Neuropharmacology Research (49 papers), Receptor Mechanisms and Signaling (30 papers), Ion channel regulation and function (17 papers), Pharmacological Receptor Mechanisms and Effects (7 papers), Photochromic and Fluorescence Chemistry (7 papers), Photoreceptor and optogenetics research (7 papers), Molecular Sensors and Ion Detection (5 papers) and Chemical Synthesis and Analysis (5 papers). The work is most often cited by research in Cellular and Molecular Neuroscience (3.8k citations), Biological Psychiatry (281 citations), Molecular Biology (2.8k citations), Cognitive Neuroscience (728 citations) and Neurology (222 citations). Bryan G. Johnson has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include Darryle D. Schoepp, James A. Monn, Rebecca A. Wright, Craig R. Salhoff, J. Paul Burnett, Nancy G. Mayne, Paul L. Ornstein, Joseph P. Tizzano, Rama M. Belagaje and Stephen Baker. Their work appears in journals such as Journal of Medicinal Chemistry, Neuropharmacology, Journal of Pharmacology and Experimental Therapeutics, Journal of Neurochemistry and Bioorganic & Medicinal Chemistry Letters.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vincent MutelBreakdown of academic impact, for papers by Mark A. VarneyBreakdown of academic impact, for papers by Frédéric KnoflachBreakdown of academic impact, for papers by Henry SershenBreakdown of academic impact, for papers by Carrie K. JonesBreakdown of academic impact, for papers by Paul L. OrnsteinBreakdown of academic impact, for papers by Alan H. GanongBreakdown of academic impact, for papers by Kevin K. OgdenBreakdown of academic impact, for papers by James A. MonnBreakdown of academic impact, for papers by James N.C. Kew